2024 BCOP Preparation Course (ACPE Credits Only)

Description:

This module will provide learners with a succinct yet comprehensive review of each major cytotoxic chemotherapeutic drug class. Information will detail mechanisms of action, mechanisms of resistance, pharmacokinetics, class and individual drug black box warning and adverse event profiles, as well as monitoring requirements. Administration specifications, renal and/or hepatic dose adjustments, REMS program requirements, and risk of secondary malignancies will be reviewed. Lastly, important patient counseling points on administration, adverse events, and monitoring will be included.

UAN#: 0465-0000-24-094-H01-P

Learning Objectives:

1. Describe the mechanisms of action, mechanisms of resistance, pharmacokinetics, administration methods, common toxicities, and monitoring parameters associated with cytotoxic chemotherapy.
2. Classify chemotherapeutic agents as cell cycle specific or nonspecific.
3. Recognize which chemotherapeutic agents require renal or hepatic dosage adjustments.
4. State relevant counseling points for each chemotherapeutic agent and appropriate plans for monitoring and treating adverse effects.

Author: Amber B. Clemmons, PharmD, BCOP, FHOPA

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

This module will review mechanisms of action, mechanisms of resistance, pharmacokinetics, and administration methods for a variety of targeted therapies including small-molecule inhibitors, monoclonal antibodies, and antibody–drug conjugates. Common toxicities, monitoring parameters, and patient counseling points will also be covered.

UAN#: 0465-0000-24-092-H01-P

Learning Objectives:

1. Describe the mechanisms of action, mechanisms of resistance, pharmacokinetics, administration methods, common toxicities, and monitoring parameters associated with targeted therapies.
2. Recognize which agents require renal or hepatic dosage adjustments.
3. Recall availability and use of companion diagnostics for mutations associated with use of targeted therapies.

Author: Rachel J. Hendrix, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

This module will review the mechanisms of action, toxicities, dosage adjustments, and important monitoring parameters of immunotherapy agents in the treatment of cancer. Strategies to manage immune-related adverse events will be examined. The role of patient selection will be discussed, including the incorporation of PD-L1 receptor testing and the use of companion diagnostics. Finally, essential information will be covered so that readers can effectively counsel patients on immunotherapy agents.

UAN#: 0465-0000-24-093-H01-P

Learning Objectives:

1. Describe the mechanisms of action, mechanisms of resistance, pharmacokinetics, administration methods, common toxicities, and monitoring parameters associated with immunotherapy.
2. Recognize which agents require renal or hepatic dosage adjustments.
3. State relevant counseling points for each chemotherapeutic agent and appropriate plans for monitoring and treating adverse effects.

Author: Jaime E. Anderson, PharmD, BCOP, CMQ

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

This module will review the mechanism of action, dosing, pharmacokinetics, monitoring, adverse effects, and supportive care of hormonal therapies. Specific drug classes that will be discussed include selective estrogen receptor modulators, selective estrogen receptor down- regulators, aromatase inhibitors, luteinizing hormone–releasing hormone agonists and antagonists, and antiandrogens. Monitoring and patient counseling points on toxicities will also be covered.

UAN#: 0465-0000-24-095-H01-P

Learning Objectives:

1. Describe the mechanisms of action, mechanisms of resistance, pharmacokinetics, administration methods, common toxicities, and monitoring parameters associated with hormonal therapy.
2. Recognize which agents require renal or hepatic dosage requirements.
3. State relevant counseling points for each chemotherapeutic agent and appropriate plans for monitoring and treating adverse effects.

Author: Kelsey Turcotte, PharmD, BCOP, BCACP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

This module provides a thorough review of current best practices, primary literature, and the design or adjustment of patient-specific pharmacotherapeutic plans, including the incorporation of newer therapies for chemotherapy-induced nausea and vomiting, will be described. Optimization of the supportive care of patients with cancer, including anticoagulation and pain management, will also be included.

UAN#: 0465-0000-24-096-H01-P

Learning Objectives:

1. Identify current literature and guideline recommendations for the management of complications of cancer or cancer therapy.
2. Recognize the mechanisms of action, administration methods, common toxicities, and monitoring  parameters associated with medications used in the supportive care of patients with cancer.
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of common complications of cancer or cancer therapy.

Author: Wiktoria Bogdanska, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

Hematology/oncology pharmacists play a crucial role in decision making regarding cancer therapy complications. This module will focus on identifying and managing the complications of cancer therapy for hematology/oncology patients, including neutropenia, infection, and the use of growth factors as primary and secondary prophylaxis. It will also cover the clinical presentation and management of bone health, and several oncologic emergencies: superior vena cava syndrome, spinal cord compression, tumor lysis syndrome, and hypercalcemia of malignancy.

UAN#: 0465-0000-24-098-H01-P

Learning Objectives:

1. Identify current literature and guideline recommendations for the management of complications of cancer or cancer therapy.
2. Recognize the mechanisms of action, administration methods, common toxicities, and monitoring parameters associated with medications used in the supportive care of patients with cancer.
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of common complications of cancer or cancer therapy.

Author: Carlo Legasto, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

This module provides a review of common pediatric malignancies, therapeutic considerations and monitoring, and the prevention and treatment of long-term toxicities pertinent to the role of pharmacotherapy specialists practicing in pediatric oncology. This module aims to advance the clinical knowledge and decision-making skills of oncology pharmacists with regard to common malignancies that affect the pediatric population and the unique survivorship concerns that this patient population faces.

UAN#: 0465-0000-24-099-H01-P

Learning Objectives:

1. Identify the etiology, pathophysiology, clinical presentation, and prognosis of common pediatric malignancies.
2. Choose an individualized therapeutic plan based on an assessment of patient information, available evidence, and treatment guidelines for common pediatric malignancies.
3. Compare expected outcomes of given therapeutic modalities (e.g., response, toxicity, survival, etc.) for common pediatric malignancies.
4. Recognize prevention, monitoring, and treatment plans for long-term toxicity associated with the treatment of pediatric malignancies.

Author: Diana Wu, PharmD, BCPS, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

It has been demonstrated in the literature that 30%–50% of all cancer cases are preventable and that prevention offers the most cost-effective long-term strategy for addressing and controlling cancer as a disease. As a result, many organizations, including the World Health Organization, the National Cancer Institute, the American Cancer Society, the American Institute for Cancer Research, the U.S. Preventive Services Task Force, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network® (NCCN®), have raised awareness of the causes of cancer and increased the focus on cancer screening and prevention. It is important for healthcare providers to know what the guidelines recommend and how to keep up with the changing technology available. This module will outline the various modifiable and nonmodifiable risk factors for cancer, discuss pharmacologic and nonpharmacologic prevention methods, and review the existing guidelines for early detection.

UAN#: 0465-0000-24-100-H01-P

Learning Objectives:

1. Outline the various modifiable and nonmodifiable risk factors associated with the multitude of oncologic malignancies.
2. Use available data to provide recommendations for various pharmacologic and nonpharmacologic interventions in cancer prevention.
3. Differentiate cancer screening recommendations from national guidelines for general versus high-risk populations.

Author: Robert Mancini, PharmD, BCOP, FHOPA

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

Because of the increased application of molecular pathways and precision medicine in the field of oncology, oncology pharmacists need to be aware of the history, current status, and future development of genomically-guided therapies. This module will educate oncology pharmacists on the role of molecular pathways in cancer development and the role of pharmacogenomics in cancer care and assess novel advances in targeted therapeutics.

UAN#: 0465-0000-24-103-H01-P

Learning Objectives:

1. Describe the clinical significance of germline and somatic mutations found by using molecular profiling techniques in patients with cancer.
2. Determine the appropriate molecular profiling test(s) to guide cancer-directed therapy in select clinical scenarios.
3. Develop an individualized therapeutic plan for a patient based on their clinical characteristics and molecular profiling results.
4. Identify cancer-directed therapies that may be impacted by pharmacogenomic variation.

Authors: Mary Walters, PharmD, BCOP, and Mark Zangardi, PharmD, MS, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

This module will focus on all aspects of the Practice Management section of the BCOP examination, covering the medication use process for hazardous drugs and key considerations for practice leaders in oncology pharmacy.

UAN#: 0465-0000-24-110-H04-P

Learning Objectives:

1. Understand the guidelines and practice standards from professional organizations for the practice of oncology pharmacy.
2. Compare the national accreditation and federal regulatory organizations’ requirements for the use of hazardous drugs in the care of patients with cancer including the safe preparation and administration of hazardous drugs.
3. Recall important components of medication purchasing, reimbursement, value-based care, and other key considerations in managing the cost-effectiveness of cancer care.
4. Examine policies and procedures required to support the needs of the patient with cancer, such as patient assistance programs and compassionate use.
5. Analyze the role that technology and automation systems can contribute to best practices in ensuring safe and quality care for the patient with cancer.

Author: Anthony M. Boyd, PharmD, BCPS

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

This module will cover the different study designs used in oncology clinical trials, including both observational and investigational designs. Different aspects of study methodology will be discussed, including internal/external validity, endpoints, and statistical analyses. This module will also discuss an overview of the FDA drug approval process and regulations pertaining to oncology research.

UAN#: 0465-0000-24-111-H04-P

Learning Objectives:

1. Recognize the different types of study designs used in oncology clinical trials.
2. Choose appropriate clinical trial endpoints and statistical analyses based on the purpose of the study.
3. Interpret the results of a clinical trial.
4. Apply the results of a clinical trial to a patient on the basis of the internal and external validity of the trial.
5. Review the FDA approval processes for drugs and biologics.

Author: Sherrill J. Brown, DVM, PharmD, BCPS

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

Progress in the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) was stagnant for decades until a boom of newly developed targeted therapies garnering U.S Food and Drug Administration (FDA) approval led to considerable shifts in treatment paradigms. This module will focus on the pathophysiology, risk stratification, and current treatment of AML, ALL, and MDS, including the role of more recently FDA-approved agents in clinical practice. Upon completion, the learner will have knowledge of the current and evolving management of AML, ALL, and MDS, including the incorporation of newer agents into guidelines and current practice standards.

UAN#: 0465-0000-24-112-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations, and staging for myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
2. Interpret patient-specific diagnostic information that dictate therapeutic treatment decisions for AML, ALL and MDS.
3. Outline the current risk stratification system for AML, ALL and MDS.
4. Choose an individualized therapeutic  plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of AML, ALL and MDS.

Author: Kayleigh R. Marx, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

This module will review the clinical management of chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), and hairy cell leukemia (HCL). The use of oral small-molecule inhibitors in both the frontline and relapsed or refractory settings for CLL will be covered. Small- molecule inhibitors for CLL have unique toxicity profiles and special considerations for use that require a multidisciplinary, patient-centered approach. Oral therapies remain the backbone of CML management as well. This module will highlight the important role that pharmacists may have in treatment selection, adherence, and toxicity monitoring for these patient populations.

UAN#: 0465-0000-24-120-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations, and staging for chronic leukemias.
2. Interpret patient-specific diagnostic information that dictate therapeutic treatment decisions for chronic leukemias.
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of chronic leukemias.
4. Modify therapeutic and monitoring plans based on patient-specific characteristics and toxicities due to treatment of chronic leukemias.

Author: Alison Duffy, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

This module will cover the basics of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and the role of HSCT in treating hematologic malignancies and selected solid tumors. Topics covered will include stem cell source, mobilization, conditioning regimen intensity and agents used, and management of short- and long-term complications, including graft-versus-host disease (GVHD), infectious complications, and adverse effects of chemotherapy. The role of haploidentical HSCT, outpatient HSCT management, novel agents for GVHD treatment and infection prophylaxis, and the role of post-HSCT maintenance therapy will be highlighted, given the increasing use in practice and recent U.S. Food and Drug Administration approvals.

UAN#: 0465-0000-24-121-H01-P

Learning Objectives:

1. Distinguish between available donor types, stem cell sources, and conditioning regimen intensity used in hematopoietic stem cell transplantation (HSCT).
2. Identify dose‐limiting toxicities associated with HSCT conditioning regimens and appropriate management strategies.
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the prevention and management of acute graft-versus-host disease (GVHD), chronic GVHD, and infections typically observed in the HSCT population.

Author: Katie Gatwood, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

This module will review the pathophysiology, clinical presentation, diagnosis and staging, and treatments for patients with newly diagnosed and relapsed or refractory lymphoma. The module will also focus on applying relevant literature to provide recommendations on the treatment of lymphoma. Patient cases will be used to demonstrate clinical pearls that are pertinent to caring for patients undergoing lymphoma treatment.

UAN#: 0465-0000-24-122-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations and staging for lymphomas
2. Interpret patient-specific diagnostic information that dictates therapeutic treatment decisions for lymphomas
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for lymphomas
4. Modify therapeutic and monitoring plans based on patient-specific characteristics and toxicities due to treatment of lymphomas.

Author: Molly Schiffer, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

This module will review and discuss the pathophysiology and epidemiology of multiple myeloma (MM), factors influencing treatment selection, symptom management, and supportive care. The module will also provide an in-depth review of the hallmark clinical trials, efficacy and safety, monitoring, adherence and compliance, and sequencing of therapies. Oncology pharmacists play an integral role in the treatment of patients with MM and should be knowledgeable about management strategies to ensure optimal outcomes.

UAN#: 0465-0000-24-123-H01-P

Learning Objectives:

1. Recognize the risk factor, clinical presentations and staging for multiple myeloma.
2. Interpret patient-specific diagnostic information that dictates therapeutic treatment decisions for multiple myeloma.
3. Outline the current risk stratification systems for multiple myeloma.
4. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for multiple myeloma.
5. Modify therapeutic and monitoring plans based on patient-specific characteristics and toxicities due to treatment of multiple myeloma.

Author: Becca LaRue, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

Genitourinary cancers, including bladder, renal cell, prostate, and testicular cancers, are commonly diagnosed in the United States. Although these cancers have in common their location in the urinary or male reproductive system, they are distinct cancers. This module will focus on the etiology, pathophysiology, and molecular biology of bladder, prostate, renal cell, and testicular cancers. Risk factors (modifiable and nonmodifiable) and appropriate prevention and screening recommendations for each cancer will be discussed. Optimal first- and subsequent-line treatment options for each stage of these cancers will be examined, and the supporting evidence and national treatment guideline recommendations will be highlighted. In addition, toxicities of these regimens will be reviewed, along with clinical and practical considerations for prevention and monitoring of these regimens in a patient-specific approach.

UAN#: 0465-0000-24-117-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations, and staging for genitourinary cancers
2. Interpret patient-specific diagnostic information that dictate therapeutic decisions in genitourinary cancers.
3. Outline the current risk stratification systems for genitourinary cancers
4. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for genitourinary cancers
5. Modify therapeutic plans based on patient-specific characteristics and toxicities due to treatment of genitourinary cancers

Author: Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

This module will review the management of breast cancer, covering the epidemiology, genomic and molecular characteristics and targets, staging, treatment, and management of toxicity during treatment.

UAN#: 0465-0000-24-116-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations, and staging for breast cancer
2. Interpret patient-specific diagnostic information that dictate therapeutic treatment decisions of breast cancer
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of breast cancer
4. Modify therapeutic plans based on patient-specific characteristics and toxicities due to treatment of breast cancer.

Author: Alison Svoboda, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

The purpose of this module is to provide a comprehensive review of gynecologic malignancies, including ovarian, cervical, and endometrial cancer. Clinical and practical considerations from a patient-specific approach will also be discussed.

UAN#: 0465-0000-24-115-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations, and staging for gynecologic malignancies.
2. Interpret patient-specific diagnostic information that dictates therapeutic treatment decisions for gynecologic malignancies.
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of gynecologic malignancies.
4. Modify therapeutic and monitoring plans on the basis of patient specific characteristics and toxicities due to the treatment of gynecologic malignancies.

Author: Emily Graham, PharmD, BCOP, MS

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

Primary brain tumors are a heterogenous group of neoplasms arising from different cells of the central nervous system (CNS). Management varies based on histology and tumor classification by the World Health Organization (WHO). Molecular parameters and patient-specific factors such as age, also affect treatment decisions. This module reviews epidemiology, pathophysiology, clinical features, classification, and diagnosis of primary brain tumors with a specific focus on gliomas and meningiomas. Current treatment guidelines and literature are covered, and the role of pharmacologic therapy in combination with radiation, surgery, and medical devices for the management of primary brain tumors is described.

UAN#: 0465-0000-24-097-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations, and staging for CNS malignancies.
2. Interpret patient-specific diagnostic information that dictates therapeutic treatment decisions for CNS malignancies.
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of CNS malignancies.

Author: Lisa Modelevsky, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

Adult sarcomas include more than 70 different subtypes but account for only 1% of all adult solid tumors. This module includes a broad overview of soft tissue sarcomas with a focus on cytotoxic and targeted therapies. The literature is evaluated and supportive care plans are developed for specific therapies. The module also reviews how identifiable genetics help guide patient-specific treatment plans.

UAN#: 0465-0000-24-114-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations, and staging for adult sarcomas
2. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of adult sarcomas.
3. Modify therapeutic and monitoring plans based on patient-specific characteristics and toxicities due to treatment of adult sarcomas.

Author: Christy S. Harris, PharmD, BCOP, FHOPA

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Knowledge

Description:

Squamous cell carcinoma of the head and neck (SCCHN) is a complex and heterogeneous group of cancers, the sixth most common cancer worldwide. Because most patients present with locally advanced disease, multimodality treatment is typically necessary and may include surgery, radiation, or systemic therapy. Treatment for SCCHN is associated with significant acute and long-term toxicities, such as severe mucositis, odynophagia, dysphagia, emesis, and xerostomia. This module will cover epidemiology, risk factors, and clinical presentation of SCCHN. It will also provide an overview of the treatment options for advanced and recurrent or metastatic SCCHN, including thyroid cancer.

UAN#: 0465-0000-24-113-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations and staging for head and neck and thyroid cancers.
2. Interpret patient-specific diagnostic information that dictates therapeutic decisions for head and neck and thyroid cancers.
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of head and neck and thyroid cancers.
4. Modify therapeutic and monitoring plans based on patient-specific characteristics and toxicities due to treatment of head and neck and thyroid cancers.

Author: Linda C. Barnachea, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

This module will review and discuss the pathophysiology and epidemiology of gastrointestinal (GI) cancers, factors influencing treatment selection, symptom management, and supportive care. The module will also provide an in-depth review of the hallmark clinical trials, efficacy and safety, monitoring parameters, and therapies used to treat lower GI cancers (colorectal and anal cancers), pancreatic cancer, upper GI cancers (esophageal, esophagogastric junction, and gastric cancers), and hepatocellular carcinoma.

UAN#: 0465-0000-24-104-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations, and staging of gastrointestinal cancers.
2. Interpret patient-specific diagnostic information that dictate therapeutic treatment decisions for gastrointestinal cancers.
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of gastrointestinal cancers.
4. Modify treatment and monitoring plans based on patient-specific characteristics and toxicities due to treatment of gastrointestinal cancers.

Author: Brooke D. Daugherty, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

Lung cancer is the second most common type of cancer behind breast cancer and prostate cancer, and it causes more cancer-related deaths than breast, prostate, and colorectal cancers combined. However, much progress has been made recently in the form of screening, targeted therapy, and immunotherapies. Understanding the pathophysiology and molecular markers has led to complex treatment combinations that have revolutionized the treatment of lung cancer. This module will review the pathophysiology, risk factors, molecular targets, and landmark clinical trials that have created current treatment guidelines and cover the adverse effects of treatments for small cell and non–small cell lung cancer. These tools will help the oncology pharmacist identify both the appropriate treatment and toxicity management strategies to help optimize treatment outcomes.

UAN#: 0465-0000-24-102-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations and staging for lung cancers
2. Interpret patient-specific diagnostic information that dictates therapeutic treatment decisions for lung cancers
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for lung cancer
4. Modify therapeutic and monitoring plans based on patient-specific characteristics and toxicities due to the treatment of lung cancers.

Author: Dan Melzer, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application

Description:

The treatment landscape for skin cancers continues to evolve, with new indications and medications being added to treatment algorithms. With multiple immunotherapy agents and targeted therapies now approved throughout the spectrum of disease treatment, it is important for the oncology pharmacist to understand the similarities and differences in dosing, toxicity profiles, monitoring, and specific patient counseling pearls with these therapies. This module will review the study data and clinical considerations for the oncology pharmacist for the treatment of advanced melanoma and discuss therapies approved for the treatment of nonmelanoma skin cancers.

UAN#: 0465-0000-24-101-H01-P

Learning Objectives:

1. Recognize the risk factors, clinical presentations and staging for skin cancers.
2. Interpret patient-specific diagnostic information that dictates therapeutic decisions for skin cancers
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of melanoma and nonmelanoma skin cancers.
4. Modify therapeutic and monitoring plans based on patient-specific characteristics and toxicities due to treatment of skin cancers.

Author: Heather Armbruster, PharmD, BCOP

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.

Activity Type: Application